CYP51 (Erg11) belongs to the cytochrome P450 monooxygenase (CYP) superfamily and
mediates a crucial step of the synthesis of ergosterol, which is a fungal-specific sterol. It is …

Prior to 1981, treatment options for invasive fungal infections were limited and associated
with significant toxicities. The introduction of ketoconazole marked the beginning of an era of …

Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum
concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 …

Background Variability in genes implicated in drug pharmacokinetics or drug response can
modulate treatment efficacy or predispose to adverse drug reactions. Besides common …

Patients undergoing treatment with immunosuppressant drugs following solid organ or
hematopoietic stem cell transplantation are at particular risk for development of serious …

Voriconazole (VCZ) use is limited by its narrow therapeutic range and significant interpatient
variability in exposure. This study aimed to assess (i) the impact of CYP2C19 genotype on …

Background Voriconazole, a first-line antifungal drug, exhibits nonlinear pharmacokinetics
(PK), together with large interindividual variability but a narrow therapeutic range, and …

Inter-ethnic differences in drug response are all too well known. These are underpinned by a
number of factors, including pharmacogenetic differences across various ethnic populations …

Objectives This analysis evaluated the variability of isavuconazole plasma concentrations
between subjects and between sampling times, and assessed their relationship to outcomes …

Over the past 15 years, there has been an increase in development and utilization of newer
antifungal agents. The ideal antifungal agent in regard to spectrum of activity …